Login or sign up
For business
Average ratingGreat
4.1/ 5

Based on 11 reviews

536%
436%
327%
20%
10%
Ask AI

Ask AI about Ventaleon

Generated with AI from 11 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Ventaleon

Ventaleon is developing inhaled treatments against viral infections. The Company’s lead therapy, is an inhaled LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well-known acetyl salicylic acid (Aspirin®), suitable as an ingredient for inhalable aerosol, has completed Phase II clinical trials to treat severe influenza.

A proof-of-concept study in influenza patients with moderate to severe symptoms demonstrated more rapid symptom decline when administered via inhaled LASAG compared to standard of care. The Company is currently preparing to enter a pivotal clinical trial with inhaled LASAG.

Ventaleon was founded as a spin-off from Activaero, a leading specialist in aerosol inhalation therapies and technologies, in 2012